Americans expect and deserve consistent healthcare product labeling, no matter what state they buy or use the items in. It is in every citizen's best interest for the federal government to retain authority over safety labeling standards. Centralized regulation removes variability and guarantees the reliability of health data listed on consumer product packaging from coast to coast.
CHPA, its educational foundation, and member companies are empowering consumers to practice responsible self-care, providing resources to help respond to this pandemic. We’re guided by these core principles.
On behalf of the Consumer Healthcare Products Association, enclosed herein are comments on the 2019 revised draft guidance document as well as FDA’s decision to revoke CPG 400.400.
Modernizing food and dietary supplement labels is in the best interest of consumers and industry alike. Supplement facts labels serve as a trusted source of information and provide a consistent way to comprehend nutrient content.
Herein CHPA provides feedback on FDA’s recent draft guidance document addressing the labeling of dietary supplements containing live microbials (also referred to as probiotics).
CHPA applauds CRN and UL for spearheading the Supplement OWL, which will prove to be a valuable resource for regulators, retailers and ultimately consumers.
CHPA appreciates the opportunity to provide information relevant to use of the term “natural” in food labeling, and believes that a formal definition will help to reduce consumer confusion and provide clarity to manufacturers and marketers making claims relying upon such a definition.
CHPA appreciates the opportunity to provide information on features to add and potential functionality improvements to make the Dietary Supplement Label Database a more useful tool for regulators, consumers, and other users of the database.
CHPA applauds FDA's efforts to amend labeling regulations for conventional foods and dietary supplements in order to provide updated nutrition information to consumers.
The Petitioners request that the Commissioner of Food and Drugs add a warning to the labeling of all nonprescription drug products containing an ingredient with “anticholinergic or histamine H1 inverse agonist effects” noting that the product can cause a confusional state.
